A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase

Status:
Completed

Trial end date:
2016-05-03

Target enrollment:

Participant gender:

This study assessed the safety and efficacy of LDK378 in adult patients with genetic abnormalities in anaplastic lymphoma kinase (ALK).

Phase 1

Novartis Pharmaceuticals

Ceritinib